Learn more about whether Open Text Corporation or Vertex, Inc. is a better investment based on AAII's A+ Investor grades, ...

Stifel Nicolaus analyst Brad Reback maintained a Hold rating on Vertex (VERX – Research Report) today and set a price target of $31.00. The ...

Morgan Stanley raised the firm’s price target on Vertex (VERX) to $60 from $57 and keeps an Overweight rating on the shares. The company’s ...

Celonis was launched in 2011. The following year, the Munich-based company participated in SAP’s Startup Focus program — the starting point of a long-term business relationship between SAP and ...

According to Reuters, the expanded partnership now enables Reddit (RDDT) to use Google’s Vertex AI, an AI development platform by Google Cloud that enables its users to build, deploy and scale ...

We are a city that drives innovation — where the scientists at Vertex invented life-changing ... Four years ago, businesses like Eli Lilly, SAP, Roche, LEGO, and NVIDIA called other cities ...

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

Goldman Sachs analyst Adam Hotchkiss expressed expectations on Vertex, Inc. (NASDAQ:VERX) ahead of its first Investor Day as a public company on March 19. The analyst reiterated the Buy rating ...

Three people with type 1 diabetes who received Vertex Pharma’s islet cell therapy VX-880 have been able to come off insulin altogether within a year, raising the prospect of a life without ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...